Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medinol v. Guidant patent trial

This article was originally published in The Gray Sheet

Executive Summary

July 10 trial date set for the U.S. District Court for the Southern District of New York to assess the validity of Medinol's '381 patent related to the flexibility of its coronary stents. If Medinol's claims hold, the jury will set damages based on Guidant's infringement of the Israeli firm's patent. Medinol was granted summary judgment on Feb. 10 that Guidant violated its patent (1"The Gray Sheet" March 6, 2006, p. 4). Once started, the trial is expected to conclude within seven trial days. The Israeli firm is asking for royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform...
Advertisement

Related Content

Medinol Strikes Twice: Guidant Entanglement May Affect Boston Scientific
Medinol Strikes Twice: Guidant Entanglement May Affect Boston Scientific
Advertisement
UsernamePublicRestriction

Register

MT023317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel